Ryan's District Boards

<p><a href="http://news.yahoo.com/gsks-crohns-disease-treatment-fails-phase-iii-trial-144635108.html"><img src="http://l2.yimg.com/bt/api/res/1.2/Y0jsublSjpPDqxKY4qxplQ--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-08-23T144635Z_1_CBRE97M151W00_RTROPTP_2_GSK-CHINA.JPG" width="130" height="86" alt="The signage for the GlaxoSmithKline building is pictured in London" align="left" title="The signage for the GlaxoSmithKline building is pictured in London" border="0" /></a>LONDON (Reuters) - British pharmaceutical group GlaxoSmithKline Plc said vercirnon, a drug it was developing to treat Crohn's disease and licensed from ChemoCentryx, had failed in a late-stage clinical trial. The medicine, which GSK licensed from the California-based company in 2010, did not improve the incidence of adverse events in patients when measured against a placebo, GSK said on Friday, and there was a trend for overall adverse events to increase as dosage levels increased. The trial failure wiped as much as $242 million, or nearly half, from ChemoCentryx's value. ...</p><br clear="all"/>